Vol. 21/No. 18 | OncologyLive

Study Endorses Benefits of Population-Based BRCA Screening

September 24, 2020


Implementing population-based BRCA1/2 testing is not only cost-effective in high- and upper middle–income countries but could also prevent tens of thousands of breast and ovarian cancer cases compared with the current clinical strategy, which recommends testing only for high-risk women.

Investigators Untangle Emerging Strategies in Gastric Cancer

September 23, 2020


Findings from clinical trials evaluating HER2-directed and immunotherapeutic approaches for treating patients with gastric cancer are among recent data attracting interest from experts in the gastrointestinal cancer field.

Community Practice Provides Model for Finding New Revenue in COVID-19 Era

September 23, 2020

The coronavirus disease 2019 pandemic is highlighting how independent community oncology practices are the best source for patients to receive care close to home, while also presenting several challenges for practices and their patients.

Pemigatinib Trial Seeks to Build on Targeted Advances in Cholangiocarcinoma

September 22, 2020


An explosion of research in the field led to the approval of pemigatinib in April 2020 for patients with unresectable, previously treated advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement.

Investigator Looks to Novel Therapy to Advance TP53-Mutant MDS Landscape

September 17, 2020

David P. Steensma, MD, discusses the importance of evaluating eprenetapopt in the pivotal phase 3 study, the agent’s potential role in the MDS landscape, and some of the questions that remain in this setting.

New Options Mark Major Strides in Treating HER2+ Metastatic Breast Cancer

September 16, 2020

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

Interest Builds for Targeting TIGIT Checkpoint

September 15, 2020


TIGIT, an inhibitory immune checkpoint that plays a central role in limiting antitumor responses, is attracting robust interest in the research community as a novel target for combination therapies across a range of cancer types, particularly solid tumors.

Traina Helps Navigate Surge of New Breast Cancer Therapies

September 14, 2020

Cover Story

Nearly 15 years have passed since pathologists at Memorial Sloan Kettering Cancer Center conducted gene expression analyses on breast cancer primary tumors and described a potential role for a novel target, which quickly became a major research focus for their colleague Tiffany A. Traina, MD.

Scramble Over COVID-19 Clinical Trials Holds Lessons for Oncology

September 12, 2020

From the Editor

Because it is likely that COVID-19 will be around for a considerable period of time, it is hoped that all involved in the clinical research establishment can view this experience as a process that needs substantial improvement.